Biotech in Austria: news and updates

News and Trends 27 Apr 2023

Australian biopharma Telix banks on AI with Dedicaid acquisition

Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University…

April 27, 2023 - 4 minutesmins - By Jim Cornall

biocatalysis pseudouridine mRNA vaccines

More News! 25 Apr 2023

More efficient and cost-effective mRNA vaccines developed

A new and patented method for the production of the important mRNA vaccine component pseudouridine is more efficient, sustainable and cost-effective than the previously used chemical synthesis. Researchers from the…

April 25, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

First toxic shock syndrome vaccine phase 2 study completed

The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to…

February 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Alcohol-related liver disease: mechanism could lead to new therapies

Alcohol-related liver disease is among the most common causes of morbidity and mortality worldwide. Due to an incomplete understanding of the factors contributing to disease development, liver transplantation is still…

January 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

New biomarker for early prediction of response to CAR-T cell therapy

A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel…

January 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 2 Dec 2022

Partnership to deliver oncology workflow for 7 European hospitals

A BC Platforms (BCP) partnership that includes Finland’s Euformatics and Hungary’s Oncompass Medicine has been awarded a contract for the second phase of developing standardized oncology workflows for a buyer…

December 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 22 Nov 2022

Arecor to start second type 2 diabetes clinical trial

Arecor Therapeutics plc says the BASG (Bundesamt für Sicherheit im Gesundheitswesen) has cleared the company’s clinical trial application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in…

November 22, 2022 - 3 minutesmins - By Jim Cornall

More News! 26 Oct 2022

Study shows ability to develop and apply targeted treatment in head and neck cancers

A joint study looked at the development identification of specific markers to improve risk assessment of patients with difficult to treat head and neck tumors. Malignant tumors in these areas…

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Oct 2022

Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants

Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants. Organ damage occurs in up to 70% of patients in the first few months…

October 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 6 Oct 2022

New approaches beckon for small cell lung cancer treatment

Small cell lung cancer (SCLC) is a particularly aggressive tumor that has so far been treated with standardized measures. However, a study led by MedUni Vienna in Austria has shown…

October 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

New drug boosts options for rheumatoid arthritis treatment

In its final phase III clinical trial, a new drug for treating rheumatoid arthritis has proved to be at least as effective as the current "gold standard" treatment for this…

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2022

From mugwort allergy to an effective vaccine?

A research team at MedUni Vienna in Austria says it has discovered key mechanisms of allergy to pollen from the common weed mugwort, which could lay the foundation for the…

June 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Feb 2022

Ribbon Biolabs Pushes DNA Synthesis Length Limits with €18M Series A

The Viennese biotech startup Ribbon Biolabs has raised an €18M Series A round to reduce the costs of synthesizing long DNA molecules, which could accelerate research into synthetic biology and…

February 1, 2022 - 3 minutesmins - By Dan Samorodnitsky

Best in Biotech 24 May 2021

The Top 15 Biotech Companies You Should Know in Vienna

Vienna has a booming life sciences sector that has rapidly grown over the last decade. Here are 15 biotech companies in Vienna you should know about. Vienna might not be…

May 24, 2021 - 10 minutesmins - By Helen Albert

News and Trends 18 Mar 2020

OncoOne Raises €13M Series A to Develop First-in-Class Cancer Treatments

Austrian startup OncoOne has closed its first round of venture capital funding after raising €13M to investigate a new treatment target against solid tumor cancers. Investment in the Series A…

March 18, 2020 - 2 minutesmins - By Anita Chakraverty

News and Trends 25 Feb 2020

European Researchers to Make Light Bulbs using Bacteria

A team of scientists from Austria, Spain, and Italy is working to make LED light bulbs out of proteins produced by bacteria. Light-emitting diodes, or LEDs, are widely seen as…

February 25, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Oct 2019

Austrian Biotech Will Develop Viral Protein For Vaginal Infection

The Austrian biotech company PhagoMed Biopharma is developing a viral protein that could one day treat the common condition bacterial vaginosis without disrupting the microbiome as traditional antibiotics do. The…

October 22, 2019 - 3 minutesmins - By Jonathan Smith

Themis Biosciences fundraising chikungunya vaccine

News and Trends 18 Sep 2019

Themis Raises €40M for First Phase III Trial of a Chikungunya Vaccine

Vienna-based Themis Biosciences has raised €40M in a Series D round to fund a phase III trial that could lead to the approval of the world’s first vaccine for chikungunya…

September 18, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Aug 2019

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp & Dohme. As part of the agreement, MSD will provide research…

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jun 2019

Austrian Biotech Raises €19M to Commercialize First Chikungunya Vaccine

The market is in sight for the first potential vaccine for the chikungunya virus, as the company Themis Bioscience will receive up to €18.7M ($21M) in non-dilutive funding to finance…

June 4, 2019 - 2 minutesmins - By Jonathan Smith

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering